X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Indian rupee, trade balance & more... - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Feb 5, 2008

    Indian rupee, trade balance & more...

    • A slumping dollar and rising inflows into the country has led the Indian rupee to appreciate considerably in the last one year. With the US Fed going on an interest rate cutting spree in a bid to prevent the US economy from going down in the doldrums, the outlook for the dollar continues to remain bleak, which means that the rupee could remain at these appreciated levels. The RBI keeping interest rates steady and the US Fed going in for rate cuts has led to the widening of interest rate differential between the two currencies. This probably strengthens the case for more FII inflows into the country.

      Having said that, given the impending recession in the US economy and its impact on other global economies, there is a possibility that foreign investors might look to protect their investments by keeping the same in cash rather than invest the same in emerging economies (including India). If this happens, and the RBI also intervenes in the forex market, any further appreciation of the rupee might get arrested. One also cannot ignore the firm crude prices, which will exert downward pressure on the rupee every month when the import payments become due.


    • India's merchandise exports posted a growth of 21.9% during the period April-November 2007. Against this, growth in imports stood at a higher 26.9% and was largely due to non-oil imports, which recorded a substantial increase of 35.3% (21.3% in the corresponding period last year). Oil imports during the said period showed a sharp deceleration in growth (9.8% as against 42.0% in April-November 2006) and could largely be attributed to the steep rupee appreciation. As a result, merchandise trade deficit during April-November 2007 ballooned to US$ 52.8 bn (US$ 38.5 bn in the corresponding period last year).

      However, the current account deficit was restricted to US$ 10.7 bn and this was largely due to robust growth in invisibles, which have considerably softened the adverse impact of a widening trade deficit. Net surplus under invisibles (services, transfers and income taken together) was higher at US$ 31.7 bn in April-September 2007 (US$ 23.4 bn in April-September 2006), reflecting mainly the rise in remittances from overseas Indians, higher interest income on reserves and relatively moderate rise in payments of business services.

      Overall, the balance of payments recorded a surplus of US$ 40.4 bn during April-September 2007 (US$ 8.6 bn during April-September 2006) due to substantial net capital flows. These largely emanated from FDI (US$ 13.8 bn), FIIs (US$ 26.8 bn in the current financial year up to Jan 11, 2008) and ECBs (US$ 10.6 bn). While the FDI money that is coming in is essential in terms of boosting economic development and generating returns, the government will have its hands full in curbing any volatility in FII inflows going forward.


    • Big Pharma's mettle continues to be tested with the US FDA becoming more stringent when it comes to approving and labeling new drugs in the market. While the controversy surrounding 'Avandia', GSK Plc's anti-diabetes drug, is well documented, the latest in the FDA's line of fire is Pfizer's smoking cessation drug 'Chantix', which has been linked to suicidal behaviours among patients taking the drug. This only further compounds the problems that Big Pharma has been facing for a while now namely, weakening drug pipeline, patent expiries of blockbuster drugs and intensifying generic competition.

      Juxtapose Indian pharma's R&D efforts against this global backdrop and it is evident that the going is not going to be easy for Indian companies. The R&D programmes of Indian pharma are still in the nascent stages in comparison to their global counterparts. The riskiness for domestic companies is also higher, as they have only four to five molecules in the pre-clinical stages, which is considerably lesser than their global peers, who have 200 odd projects under various stages of development.

     

     

    Equitymaster requests your view! Post a comment on "Indian rupee, trade balance & more...". Click here!

      
     

    More Views on News

    How to Ride Alongside India's Best Fund Managers (The 5 Minute Wrapup)

    Jun 10, 2017

    Forty Indian investing gurus, as worthy of imitation as the legendary Peter Lynch, can help you get rich in the stock market.

    Why NOW Is the WORST Time for Index Investing (The 5 Minute Wrapup)

    Aug 18, 2017

    Buying the index now will hardly help make money in stocks even in ten years.

    Trump Takes a Beating (Vivek Kaul's Diary)

    Aug 18, 2017

    Donald J Trump, a wrasslin' fan, took a 'Holy Sh*t!' blow on Tuesday.

    How To Read Your Mutual Fund Account Statement Correctly (Outside View)

    Aug 17, 2017

    PersonalFN simplifies the mutual fund account statement for you.

    This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process) (The 5 Minute Wrapup)

    Aug 17, 2017

    A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    S&P BSE SENSEX


    Aug 18, 2017 03:16 PM

    MARKET STATS